An investigational cancer vaccine has demonstrated a significant overall survival benefit in patients with acute myeloid leukemia (AML), offering new evidence for an immunotherapy approach in patients who have achieved remission after relapse.
Recently, SELLAS Life Sciences announced positive topline results from the pivotal Phase 3 REGAL trial, showing that galinpepimut-S (GPS), a therapeutic vaccine targeting the WT1 protein, significantly improved overall survival compared with investigator-selected best available treatment.
Patients receiving GPS achieved a median overall survival of 24.0 months, compared with 14.7 months in the control group, representing a 9.3-month difference and a 41% reduction in the hazard of death.
The findings are particularly relevant for patients in their second or later remission who cannot undergo allogeneic stem cell transplantation, a population with limited treatment options.
Phase 3 REGAL Trial Meets Its Primary Endpoint
The global, randomized, open-label Phase 3 REGAL trial (NCT04229979) evaluated galinpepimut-S as maintenance monotherapy in patients with AML who had achieved a second or later complete remission, including remission with insufficient platelet recovery, following salvage treatment.
A total of 126 patients were randomized in a 1:1 ratio to receive GPS or investigator’s choice of best available treatment.
The control arm included observation, hypomethylating agents, venetoclax, low-dose cytarabine, or combinations of these treatments.
The primary endpoint was overall survival, with the final analysis conducted following the prespecified occurrence of 80 deaths.
Key efficacy findings included:
- Median overall survival with galinpepimut-S: 24.0 months
- Median overall survival with best available treatment: 14.7 months
- Hazard ratio for death: 0.59, corresponding to a 41% reduction in the hazard of death
- Statistical significance: Two-sided p = 0.035
SELLAS reported that the treatment groups were balanced for prognostic stratification factors. Only a limited number of patients subsequently underwent hematopoietic stem cell transplantation, with those patients equally distributed between the two groups.
The trial therefore met its primary endpoint, providing randomized Phase 3 evidence of a survival benefit with WT1-targeted therapeutic vaccination in this selected AML population.
How Does the Galinpepimut-S Cancer Vaccine Work?
Unlike conventional cancer treatments that primarily target malignant cells through cytotoxic or molecular mechanisms, galinpepimut-S is designed to stimulate the patient’s immune system to recognize and attack residual leukemia cells.
GPS targets Wilms tumor 1 (WT1), a protein commonly expressed in AML cells and several other malignancies.
Developed through research at Memorial Sloan Kettering Cancer Center (MSK), the vaccine consists of four WT1-derived peptides designed to activate both CD4+ and CD8+ T-cell immune responses across multiple human leukocyte antigen types.
The treatment is an off-the-shelf therapeutic vaccine, meaning that it does not require individual vaccine manufacturing based on each patient’s tumor.
Its purpose is not to prevent leukemia from developing in healthy individuals. Instead, GPS is being investigated as a maintenance treatment after remission, when residual malignant cells may remain despite successful initial treatment.
By stimulating immune recognition of WT1-expressing cells, researchers aim to improve disease control and prolong survival.
The vaccine originated in the laboratory of David A. Scheinberg, MD, PhD, at Memorial Sloan Kettering Cancer Center. MSK licensed GPS to SELLAS in 2014 for further clinical development.
Commenting on the results, Scheinberg stated:
“These data bring us closer to having the first off-the-shelf vaccine for cancer patients.”
Why These Findings Matter for Acute Myeloid Leukemia
AML remains a challenging hematologic malignancy, particularly in patients who experience relapse after initial therapy.
Although salvage treatments can produce subsequent remissions, maintaining those remissions and improving long-term survival remain important clinical challenges.
Allogeneic hematopoietic stem cell transplantation offers a potentially curative approach for selected patients, but it is not feasible for everyone because of medical fitness, donor availability, or other clinical factors.
This creates a need for maintenance strategies that can be administered following salvage treatment.
The REGAL findings suggest that therapeutic vaccination against WT1 may be one such strategy, providing an immune-based approach to prolonging survival in patients who have already achieved remission.
Members of the REGAL Study Steering Committee emphasized the clinical challenges faced by this population:
“Patients with AML in second remission who cannot undergo allogeneic stem cell transplantation face poor survival outcomes”
The committee includes Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, the trial’s global principal investigator; Javier Pinilla-Ibarz, MD, PhD, of Moffitt Cancer Center; and M. Yair Levy, MD, of Texas Oncology-Baylor Charles A. Sammons Cancer Center.
For further context on the treatment landscape, read OncoDaily’s overview on Acute Myeloid Leukemia in 2026.
What Did the REGAL Trial Show About Safety?
According to SELLAS, galinpepimut-S was generally well tolerated, with no new safety signals identified.
Treatment-related adverse events were predominantly grade 1 or 2, with local injection-site reactions reported most frequently.
The company described the safety findings as consistent with previous clinical experience.
However, comprehensive safety results, including detailed adverse-event frequencies, have not yet been released.
The initial announcement also did not provide detailed results for secondary endpoints such as leukemia-free survival, measurable residual disease, and antigen-specific T-cell responses.
These analyses will be important for understanding the relationship between the vaccine’s immune activity, disease control, and the observed survival benefit.
The findings currently represent topline company-reported results rather than a complete peer-reviewed analysis. Further information, including the confidence interval around the reported overall survival hazard ratio and the outcomes associated with different control treatments, will help clarify the results.
FDA Discussions and Potential Regulatory Submission in 2027
Following the positive Phase 3 results, SELLAS announced plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for galinpepimut-S.
The company is preparing for a potential Biologics License Application submission during the first half of 2027, while exploring an accelerated filing strategy.
Additional prespecified analyses and secondary endpoint evaluations are ongoing. SELLAS expects to present more comprehensive findings at an upcoming major medical conference and submit the data for publication in a peer-reviewed journal.
Importantly, GPS remains an investigational therapy and has not received FDA approval for AML.
A New Direction for Cancer Vaccines in Leukemia?
The REGAL results contribute to growing clinical evidence supporting therapeutic cancer vaccines as a potential approach for treating residual disease.
Unlike vaccines designed to prevent infection-associated cancers, galinpepimut-S is intended to generate an immune response against malignant cells that may remain after treatment.
Its off-the-shelf formulation also distinguishes it from personalized cancer vaccines, which require patient-specific development and manufacturing.
The Phase 3 survival findings provide an important clinical signal for WT1-targeted vaccination, although confirmation through full data presentation, peer review, and regulatory evaluation remains necessary.
For patients with AML who achieve a second or later remission but cannot proceed to transplantation, the results raise the possibility of a new maintenance treatment option.
The next question is whether the survival advantage demonstrated in REGAL will translate into regulatory approval and a clinically available treatment for this high-risk AML population.
Read further on OncoDaily: Acute Myeloid Leukemia: Genetic Origins May Trace Back Decades Before Diagnosis

